237 related articles for article (PubMed ID: 9290961)
1. Analysis of the fragile histidine triad gene in primary gastric carcinomas and gastric carcinoma cell lines.
Tamura G; Sakata K; Nishizuka S; Maesawa C; Suzuki Y; Iwaya T; Terashima M; Saito K; Satodate R
Genes Chromosomes Cancer; 1997 Sep; 20(1):98-102. PubMed ID: 9290961
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.
Ahmadian M; Wistuba II; Fong KM; Behrens C; Kodagoda DR; Saboorian MH; Shay J; Tomlinson GE; Blum J; Minna JD; Gazdar AF
Cancer Res; 1997 Sep; 57(17):3664-8. PubMed ID: 9288768
[TBL] [Abstract][Full Text] [Related]
3. FHIT gene and the FRA3B region are not involved in the genetics of renal cell carcinomas.
Bugert P; Wilhelm M; Kovacs G
Genes Chromosomes Cancer; 1997 Sep; 20(1):9-15. PubMed ID: 9290948
[TBL] [Abstract][Full Text] [Related]
4. Identification of unstable sequences within the common fragile site at 3p14.2: implications for the mechanism of deletions within fragile histidine triad gene/common fragile site at 3p14.2 in tumors.
Corbin S; Neilly ME; Espinosa R; Davis EM; McKeithan TW; Le Beau MM
Cancer Res; 2002 Jun; 62(12):3477-84. PubMed ID: 12067991
[TBL] [Abstract][Full Text] [Related]
5. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors.
Greenspan DL; Connolly DC; Wu R; Lei RY; Vogelstein JT; Kim YT; Mok JE; Muñoz N; Bosch FX; Shah K; Cho KR
Cancer Res; 1997 Nov; 57(21):4692-8. PubMed ID: 9354423
[TBL] [Abstract][Full Text] [Related]
6. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.
Fong KM; Biesterveld EJ; Virmani A; Wistuba I; Sekido Y; Bader SA; Ahmadian M; Ong ST; Rassool FV; Zimmerman PV; Giaccone G; Gazdar AF; Minna JD
Cancer Res; 1997 Jun; 57(11):2256-67. PubMed ID: 9187130
[TBL] [Abstract][Full Text] [Related]
7. Loss of FHIT expression in gastric carcinoma.
Baffa R; Veronese ML; Santoro R; Mandes B; Palazzo JP; Rugge M; Santoro E; Croce CM; Huebner K
Cancer Res; 1998 Oct; 58(20):4708-14. PubMed ID: 9788626
[TBL] [Abstract][Full Text] [Related]
8. FHIT gene alterations in esophageal cancer and ulcerative colitis (UC).
Zou TT; Lei J; Shi YQ; Yin J; Wang S; Souza RF; Kong D; Shimada Y; Smolinski KN; Greenwald BD; Abraham JM; Harpaz N; Meltzer SJ
Oncogene; 1997 Jul; 15(1):101-5. PubMed ID: 9233782
[TBL] [Abstract][Full Text] [Related]
9. A novel approach to simultaneously scan genes at fragile sites.
Willem P; Brown J; Schouten J
BMC Cancer; 2006 Aug; 6():205. PubMed ID: 16895604
[TBL] [Abstract][Full Text] [Related]
10. Frequent homozygous deletions in the FRA3B region in tumor cell lines still leave the FHIT exons intact.
Wang L; Darling J; Zhang JS; Qian CP; Hartmann L; Conover C; Jenkins R; Smith DI
Oncogene; 1998 Feb; 16(5):635-42. PubMed ID: 9482109
[TBL] [Abstract][Full Text] [Related]
11. Positions of chromosome 3p14.2 fragile sites (FRA3B) within the FHIT gene.
Zimonjic DB; Druck T; Ohta M; Kastury K; Croce CM; Popescu NC; Huebner K
Cancer Res; 1997 Mar; 57(6):1166-70. PubMed ID: 9067288
[TBL] [Abstract][Full Text] [Related]
12. Alterations of the FHIT gene in human hepatocellular carcinoma.
Yuan BZ; Keck-Waggoner C; Zimonjic DB; Thorgeirsson SS; Popescu NC
Cancer Res; 2000 Feb; 60(4):1049-53. PubMed ID: 10706123
[TBL] [Abstract][Full Text] [Related]
13. Altered expression of the fragile histidine triad gene in primary gastric adenocarcinomas.
Lee SH; Kim WH; Kim HK; Woo KM; Nam HS; Kim HS; Kim JG; Cho MH
Biochem Biophys Res Commun; 2001 Jun; 284(3):850-5. PubMed ID: 11396980
[TBL] [Abstract][Full Text] [Related]
14. FHIT gene in gastric cancer: association with tumour progression and prognosis.
Noguchi T; Müller W; Wirtz HC; Willers R; Gabbert HE
J Pathol; 1999 Aug; 188(4):378-81. PubMed ID: 10440747
[TBL] [Abstract][Full Text] [Related]
15. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer.
Burke L; Khan MA; Freedman AN; Gemma A; Rusin M; Guinee DG; Bennett WP; Caporaso NE; Fleming MV; Travis WD; Colby TV; Trastek V; Pairolero PC; Tazelaar HD; Midthun DE; Liotta LA; Harris CC
Cancer Res; 1998 Jun; 58(12):2533-6. PubMed ID: 9635574
[TBL] [Abstract][Full Text] [Related]
16. Precise localization of the FHIT gene to the common fragile site at 3p14.2 (FRA3B) and characterization of homozygous deletions within FRA3B that affect FHIT transcription in tumor cell lines.
Ong ST; Fong KM; Bader SA; Minna JD; Le Beau MM; McKeithan TW; Rassool FV
Genes Chromosomes Cancer; 1997 Sep; 20(1):16-23. PubMed ID: 9290949
[TBL] [Abstract][Full Text] [Related]
17. Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas.
Michael D; Beer DG; Wilke CW; Miller DE; Glover TW
Oncogene; 1997 Oct; 15(14):1653-9. PubMed ID: 9349498
[TBL] [Abstract][Full Text] [Related]
18. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
[TBL] [Abstract][Full Text] [Related]
19. Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines.
Mao L; Fan YH; Lotan R; Hong WK
Cancer Res; 1996 Nov; 56(22):5128-31. PubMed ID: 8912845
[TBL] [Abstract][Full Text] [Related]
20. Frequent breakpoints in the 3p14.2 fragile site, FRA3B, in pancreatic tumors.
Shridhar R; Shridhar V; Wang X; Paradee W; Dugan M; Sarkar F; Wilke C; Glover TW; Vaitkevicius VK; Smith DI
Cancer Res; 1996 Oct; 56(19):4347-50. PubMed ID: 8813121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
